A longitudinal study of motor performance and striatal [18F]fluorodopa uptake in Parkinson’s disease

详细信息    查看全文

• 作者：Catherine L. Gallagher (1) (2)
  Sterling C. Johnson (3) (4)
  Barbara B. Bendlin (3) (4)
  Moo K. Chung (5) (6)
  James E. Holden (7)
  Terrence R. Oakes (6)
  Benjamin R. Brooks (8)
  Richard A. Konopacki (5)
  Selami Dogan (9)
  James H. Abbs (2)
  Guofan Xu (3) (4)
  Robert J. Nickles (7)
  Robert W. Pyzalski (10)
  Onofre T. DeJesus (7)
  W. Douglas Brown (11)
  
• 关键词：Fluorodopa ; Motor control ; Parkinson’s disease ; Positron emission tomography ; Ageing ; Tongue/*physiopathology ; Facial Muscles/*physiopathology
• 刊名：Brain Imaging and Behavior
• 出版年：2011
• 出版时间：September 2011
• 年：2011
• 卷：5
• 期：3
• 页码：203-211
• 全文大小：366KB
• 参考文献：1. Aarsland, D., & Kurz, M. W. (2009). The epidemiology of dementia associated with Parkinson disease. / J Neurol Sci.
  2. Alexander, G. E., DeLong, M. R., & Strick, P. L. (1986). Parallel organization of functionally segregated circuits linking basal ganglia and cortex. / Annual Review of Neuroscience, 9, 357-81. CrossRef
  3. Barlow, S. M., & Abbs, J. H. (1984). Orofacial fine motor control impairments in congenital spasticity: evidence against hypertonus-related performance deficits. / Neurology, 34(2), 145-50.
  4. Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., & Seitelberger, F. (1973). Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. / Journal of the Neurological Sciences, 20(4), 415-55. CrossRef
  5. Braak, H., Del Tredici, K., Rub, U., de Vos, R. A., Jansen Steur, E. N., & Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson’s disease. / Neurobiology of Aging, 24(2), 197-11. CrossRef
  6. Brown, W. D., Taylor, M. D., Roberts, A. D., Oakes, T. R., Schueller, M. J., Holden, J. E., et al. (1999). FluoroDOPA PET shows the nondopaminergic as well as dopaminergic destinations of levodopa. / Neurology, 53(6), 1212-218.
  7. Bruck, A., Aalto, S., Nurmi, E., Vahlberg, T., Bergman, J., & Rinne, J. O. (2006). Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson’s disease: a two-year follow-up study. / Movement Disorders, 21(7), 958-63. CrossRef
  8. Carbon, M., Felice Ghilardi, M., Dhawan, V., & Eidelberg, D. (2007). Correlates of movement initiation and velocity in Parkinson’s disease: a longitudinal PET study. / Neuroimage, 34(1), 361-70. CrossRef
  9. Connor, N. P., Russell, J. A., Wang, H., Jackson, M. A., Mann, L., & Kluender, K. (2009). Effect of tongue exercise on protrusive force and muscle fiber area in aging rats. / Journal of Speech, Language, and Hearing Research, 52(3), 732-44. CrossRef
  10. Crow, H. C., & Ship, J. A. (1996). Tongue strength and endurance in different aged individuals. / The Journals of Gerontology. Series A: Biological Sciences and Medical Sciences, 51(5), M247-50. CrossRef
  11. de la Fuente-Fernandez, R., Kishore, A., Calne, D. B., Ruth, T. J., & Stoessl, A. J. (2000). Nigrostriatal dopamine system and motor lateralization. / Behavioural Brain Research, 112(1-), 63-8. CrossRef
  12. Desmurget, M., Grafton, S. T., Vindras, P., Grea, H., & Turner, R. S. (2003). Basal ganglia network mediates the control of movement amplitude. / Experimental Brain Research, 153(2), 197-09. CrossRef
  13. Diederich, N. J., Moore, C. G., Leurgans, S. E., Chmura, T. A., & Goetz, C. G. (2003). Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. / Archives of Neurology, 60(4), 529-33. CrossRef
  14. Draper, I. T., & Johns, R. J. (1964). The disordered movement in Parkinsonism and the effect of drug treatment. / Bulletin of the Johns Hopkins Hospital, 115, 465-80.
  15. El Sharkawi, A., Ramig, L., Logemann, J. A., Pauloski, B. R., Rademaker, A. W., Smith, C. H., et al. (2002). Swallowing and voice effects of Lee Silverman Voice Treatment (LSVT): a pilot study. / Journal of Neurology, Neurosurgery and Psychiatry, 72(1), 31-6. CrossRef
  16. Elbaz, A., Bower, J. H., Maraganore, D. M., McDonnell, S. K., Peterson, B. J., Ahlskog, J. E., et al. (2002). Risk tables for Parkinsonism and Parkinson’s disease. / Journal of Clinical Epidemiology, 55(1), 25-1. CrossRef
  17. Evarts, E. V., Teravainen, H., & Calne, D. B. (1981). Reaction time in Parkinson’s disease. / Brain, 104(Pt 1), 167-86. CrossRef
  18. Fahn, S., Elton, R. L., & Members, U. P. (1987). Unified Parkinson’s Disease Rating Scale. In S. Fahn, C. D. Marsden, M. Goldstein, & D. B. Calne (Eds.), / Recent developments in Parkinsons disease (Vol. 2, p. 153-63, 293-04). Florham Park: McMillan Healthcare Information.
  19. Flowers, K. (1975). Ballistic and corrective movements on an aiming task. Intention tremor and parkinsonian movement disorders compared. / Neurology, 25(5), 413-21.
  20. Gentil, M., Tournier, C. L., Pollak, P., & Benabid, A. L. (1999). Effect of bilateral subthalamic nucleus stimulation and dopatherapy on oral control in Parkinson’s disease. / European Neurology, 42(3), 136-40. CrossRef
  21. Gibb, W. R., & Lees, A. J. (1988). The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. / Journal of Neurology, Neurosurgery and Psychiatry, 51(6), 745-52. CrossRef
  22. Hallett, M., & Khoshbin, S. (1980). A physiological mechanism of bradykinesia. / Brain, 103(2), 301-14. CrossRef
  23. Hauber, W., & Schmidt, W. J. (1994). Differential effects of lesions of the dorsomedial and dorsolateral caudate-putamen on reaction time performance in rats. / Behavioural Brain Research, 60(2), 211-15. CrossRef
  24. Hoehn, M. M., & Yahr, M. D. (1967). Parkinsonism: onset, progression and mortality. / Neurology, 17(5), 427-42.
  25. Lasker, A. G., & Zee, D. S. (1997). Ocular motor abnormalities in Huntington’s disease. / Vision Research, 37(24), 3639-645. CrossRef
  26. Levy, G., Louis, E. D., Cote, L., Perez, M., Mejia-Santana, H., Andrews, H., et al. (2005). Contribution of aging to the severity of different motor signs in Parkinson disease. / Archives of Neurology, 62(3), 467-72. CrossRef
  27. Marek, K., Innis, R., van Dyck, C., Fussell, B., Early, M., Eberly, S., et al. (2001). [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression. / Neurology, 57(11), 2089-094.
  28. Montgomery, E. B., Jr., Nuessen, J., & Gorman, D. S. (1991). Reaction time and movement velocity abnormalities in Parkinson’s disease under different task conditions. / Neurology, 41(9), 1476-481.
  29. Morrish, P. K., Sawle, G. V., & Brooks, D. J. (1996a). An [18F]dopa-PET and clinical study of the rate of progression in Parkinson’s disease. / Brain, 119(Pt 2), 585-91. CrossRef
  30. Morrish, P. K., Sawle, G. V., & Brooks, D. J. (1996b). Regional changes in [18F]dopa metabolism in the striatum in Parkinson’s disease. / Brain, 119(Pt 6), 2097-103. CrossRef
  31. Nagasawa, H., Saito, H., Kogure, K., Hatazawa, J., Itoh, M., Fujiwara, T., et al. (1993). 6-[18F]fluorodopa metabolism in patients with hemiparkinsonism studied by positron emission tomography. / Journal of the Neurological Sciences, 115(2), 136-43. CrossRef
  32. Nocera, J., Horvat, M., & Ray, C. T. (2009). Effects of home-based exercise on postural control and sensory organization in individuals with Parkinson disease. / Parkinsonism Relat Disord.
  33. O’Day, C., Frank, E., Montgomery, A., Nichols, M., & McDade, H. (2005). Repeated tongue and hand strength measurements in normal adults and individuals with Parkinson’s disease. / Intenational Journal of Orofacial Myology, 31, 15-5.
  34. Patlak, C. S., & Blasberg, R. G. (1985). Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. / Journal of Cerebral Blood Flow Metabolism, 5(4), 584-90. CrossRef
  35. Pirker, W. (2003). Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it? / Movement Disorders, 18(Suppl 7), S43-1. CrossRef
  36. Rinne, J. O., Portin, R., Ruottinen, H., Nurmi, E., Bergman, J., Haaparanta, M., et al. (2000). Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study. / Archives of Neurology, 57(4), 470-75. CrossRef
  37. Russmann, H., Ghika, J., Villemure, J. G., Robert, B., Bogousslavsky, J., Burkhard, P. R., et al. (2004). Subthalamic nucleus deep brain stimulation in Parkinson disease patients over age 70?years. / Neurology, 63(10), 1952-954.
  38. Seibyl, J. P., Marek, K. L., Quinlan, D., Sheff, K., Zoghbi, S., Zea-Ponce, Y., et al. (1995). Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson’s disease. / Annals of Neurology, 38(4), 589-98. CrossRef
  39. Solomon, N., Lorell, D., Robin, D., Rodnitzky, R., & Luscheni, E. (1995). Tongue strength and endurance in mild to moderate Parkinson’s disease. / Journal of medical Speech-Language Pathology, 3, 15-6.
  40. Stelmach, G. E., Teasdale, N., Phillips, J., & Worringham, C. J. (1989). Force production characteristics in Parkinson’s disease. / Experimental Brain Research, 76(1), 165-72. CrossRef
  41. Tunik, E., Houk, J. C., & Grafton, S. T. (2009). Basal ganglia contribution to the initiation of corrective submovements. / Neuroimage, 47(4), 1757-766. CrossRef
  42. Van Dyck, C. H., Avery, R. A., MacAvoy, M. G., Marek, K. L., Quinlan, D. M., Baldwin, R. M., et al. (2008). Striatal dopamine transporters correlate with simple reaction time in elderly subjects. / Neurobiology of Aging, 29, 1237-246. CrossRef
  43. Vingerhoets, F. J., Schulzer, M., Calne, D. B., & Snow, B. J. (1997). Which clinical sign of Parkinson’s disease best reflects the nigrostriatal lesion? / Annals of Neurology, 41(1), 58-4. CrossRef
  44. Whone, A. L., Watts, R. L., Stoessl, A. J., Davis, M., Reske, S., Nahmias, C., et al. (2003). Slower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study. / Annals of Neurology, 54(1), 93-01. CrossRef
  45. Wing, A. M. (1988). A comparison of the rate of pinch grip force increases and decreases in Parkinsonian bradykinesia. / Neuropsychologica, 26(3), 479-82. CrossRef
  46. Yousefi, B., Tadibi, V., Khoei, A. F., & Montazeri, A. (2009). Exercise therapy, quality of life, and activities of daily living in patients with Parkinson disease: a small scale quasi-randomised trial. / Trials, 10, 67. CrossRef
  47. Yust-Katz, S., Tesler, D., Treves, T. A., Melamed, E., & Djaldetti, R. (2008). Handedness as a predictor of side of onset of Parkinson’s disease. / Parkinsonism & Related Disorders, 14(8), 633-35. CrossRef
  
• 作者单位：Catherine L. Gallagher (1) (2)
  Sterling C. Johnson (3) (4)
  Barbara B. Bendlin (3) (4)
  Moo K. Chung (5) (6)
  James E. Holden (7)
  Terrence R. Oakes (6)
  Benjamin R. Brooks (8)
  Richard A. Konopacki (5)
  Selami Dogan (9)
  James H. Abbs (2)
  Guofan Xu (3) (4)
  Robert J. Nickles (7)
  Robert W. Pyzalski (10)
  Onofre T. DeJesus (7)
  W. Douglas Brown (11)
  
  1. William S. Middleton Memorial Veterans Hospital, 6112B, 2500 Overlook Terrace Dr., Madison, WI, 53792, USA
  2. Department of Neurology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
  3. Department of Medicine, University of Wisconsin, Madison, WI, USA
  4. Geriatric Research Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, WI, USA
  5. Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI, USA
  6. Waisman Center for Brain Imaging and Behavior, Madison, WI, USA
  7. Department of Medical Physics, University of Wisconsin, Madison, WI, USA
  8. Carolinas Neuromuscular/ALS-MDA Center, Charlotte, NC, USA
  9. Aurora Sinai Medical Center, Milwaukee, WI, USA
  10. Department of Radiology, University of Wisconsin, Madison, WI, USA
  11. Department of Radiology, Medical College of Wisconsin, Milwaukee, WI, USA
  

文摘

Although [18F]fluoro-l-dopa [FDOPA] positron emission tomography (PET) has been used as a surrogate outcome measure in Parkinson’s disease therapeutic trials, this biomarker has not been proven to reflect clinical status longitudinally. We completed a retrospective analysis of relationships between computerized sampling of motor performance, FDOPA PET, and clinical outcome scales, repeated over 4?years, in 26 Parkinson’s disease (PD) patients and 11 healthy controls. Mixed effects analyses showed that movement time and tongue strength best differentiated PD from control subjects. In the treated PD cohort, motor performance measures changed gradually in contrast to a steady decline in striatal FDOPA uptake. Prolonged reaction and movement time were related to lower caudate nucleus FDOPA uptake, and abnormalities in hand fine force control were related to mean striatal FDOPA uptake. These findings provide evidence that regional loss of nigrostriatal inputs to frontostriatal networks affects specific aspects of motor function.